Test Code LAB977 Dihydrotestosterone, Serum
Additional Codes
DIHYDROTES
Reporting Name
Dihydrotestosterone, SSCH Clinical System Name: Dihydrotestosterone
Useful For
Monitoring patients receiving 5-alpha reductase inhibitor therapy or chemotherapy
Evaluating patients with possible 5-alpha reductase deficiency
Specimen Required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot serum into a plastic vial.
Collect 2.0 mL whole blood in a Red top.
Specimen Type
SerumSpecimen Minimum Volume
0.6 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Refrigerated (preferred) | 28 days |
Frozen | 90 days | |
Ambient | 28 days |
Day(s) Performed
Monday, Wednesday, Friday
TAT: 4 - 10 days
Performing Laboratory

Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Portions of this test are covered by patents held by Quest Diagnostics
Method Description
The assay uses high performance liquid chromatography with triple quadrupole tandem mass spectrometry. Deuterated stable isotope of dihydrotestosterone (13C3-DHT) is added to a 0.5 mL serum sample as internal standard. The DHT and internal standard are extracted from the sample by liquid/liquid extraction. This is followed by high performance liquid chromatography on a Cohesive LX4 System and analysis on a tandem mass spectrometer equipped with an electrospray ion source.(Unpublished Mayo Method)
Reference Values
Males
Cord blood: ≤100 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
12.1 years |
≤200 |
Stage III |
13.6 years |
80-330 |
Stage IV |
15.1 years |
220-520 |
Stage V |
18 years |
240-650 |
>19 years: 112-955 pg/mL
Females
Cord blood: ≤50 pg/mL
≤6 months: ≤1,200 pg/mL
Tanner Stages
Mean |
Age |
Reference range (pg/mL) |
Stage I (>6 months and prepubertal) |
7.1 years |
≤50 |
Stage II |
10.5 years |
≤300 |
Stage III |
11.6 years |
≤300 |
Stage IV |
12.3 years |
≤300 |
Stage V |
14.5 years |
≤300 |
20-55 years: ≤300 pg/mL
>55 years: ≤128 pg/mL
1. Pang S, Levine LS, Chow D, Sagiani F, Saenger P, New MI. Dihydrotestosterone and its relationship to testosterone in infancy and childhood. J Clin Endocrinol Metab. 1979;48(5):821-826
2. Stanczyk FZ. Diagnosis of hyperandrogenism: biochemical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):177-191
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
82642
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
DHTS | Dihydrotestosterone, S | 1848-1 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
81479 | Dihydrotestosterone, S | 1848-1 |
Testing Algorithm
For more information see Steroid Pathways.
Special Instructions
Report Available
2 to 8 daysReject Due To
Gross hemolysis | OK |
Gross lipemia | OK |
Gross icterus | OK |
Aliases: 5-a-dihydrotestosterone; 5-Alpha-Dihydrotestosterone; Allodihydrotestosterone; Androstanolone; DHT; Serum Dihydrotestosterone; Stanolone